These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37904699)

  • 1. The role of inflammatory factors and T-cell subsets in the diagnosis of recurrence in epithelial ovarian cancer patients and the effect of olaparin treatment on them.
    Maowulieti G; Zhao S; Zhao M; Yuan H
    Immun Inflamm Dis; 2023 Oct; 11(10):e1059. PubMed ID: 37904699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of Correlation of Immune T Cell Subsets, TNF-α, IFN-γ and sFas levels with Severity and Prognosis in Aplastic Anemia Patients].
    Su AY; Yang XZ; Zhang MH; DI ZX; Li Q
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1459-1464. PubMed ID: 30295268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-γ and tumor necrosis factor-α promote the ability of human placenta-derived mesenchymal stromal cells to express programmed death ligand-2 and induce the differentiation of CD4(+)interleukin-10(+) and CD8(+)interleukin-10(+)Treg subsets.
    Li H; Wang W; Wang G; Hou Y; Xu F; Liu R; Wang F; Xue J; Hu T; Luan X
    Cytotherapy; 2015 Nov; 17(11):1560-71. PubMed ID: 26432559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
    Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
    Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
    Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical efficacy and T-lymphocyte subset, serum interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), interleukin-2(IL-2) levels on treatment of chronic aplastic anemia patients by shenfu injection combined with stanozol and cyclosporin A].
    Wang SY; Wei YF; Du HL; Ren LL; Li SH
    Zhongguo Zhong Yao Za Zhi; 2005 Mar; 30(5):383-5. PubMed ID: 15806975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The regulatory function of tumor-infiltrating Th9 cells to anti-tumor activity of CD8(+) T cells in patients with gastric cancer].
    Sun PS; Gao ZJ; Fan LX; Liu YF; Chen BH; Mu SZ; Yan ZQ
    Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1186-1193. PubMed ID: 36380667
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects on the immune system and toxicity of carboplatin/paclitaxel combination chemotherapy in patients with stage III-IV ovarian and non small cell lung cancer and its role in survival and toxicity.
    Hatziveis K; Tourlakis D; Hountis P; Kyriazanos I; Sougleri M; Ginopoulos P; Camoutsis C
    J BUON; 2012; 17(1):143-8. PubMed ID: 22517709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifunctional, TNF-α and IFN-γ-Secreting CD4 and CD8 T Cells and CD8
    Rodrigues LS; Barreto AS; Bomfim LGS; Gomes MC; Ferreira NLC; da Cruz GS; Magalhães LS; de Jesus AR; Palatnik-de-Sousa CB; Corrêa CB; de Almeida RP
    Front Immunol; 2021; 12():773983. PubMed ID: 34777391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
    Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
    Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The correlation of GluR3B antibody with T lymphocyte subsets and inflammatory factors and their role in the progression of epilepsy.
    Lai Q; Wang N; Wang B; Chen Y
    J Transl Med; 2024 Sep; 22(1):877. PubMed ID: 39350251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of ash2 (absent, small, or homeotic)-like and Jumonji domain-containing protein 3 on histone methylation of interferon-gamma gene and their associations with vascular damage of Kawasaki disease].
    Mei JH; Tang G; Wang Q; Wen PQ; Xu MG; Cui D; Ma DL; Liu C; Wang GB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Sep; 45(9):791-798. PubMed ID: 29036979
    [No Abstract]   [Full Text] [Related]  

  • 14. IL-6, IFN-gamma and TNF-alpha production by liver-associated T cells and acute liver injury in rats administered concanavalin A.
    Cao Q; Batey R; Pang G; Russell A; Clancy R
    Immunol Cell Biol; 1998 Dec; 76(6):542-9. PubMed ID: 9893032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory and effector T cell subsets in tumor-draining lymph nodes of patients with squamous cell carcinoma of head and neck.
    Norouzian M; Mehdipour F; Ashraf MJ; Khademi B; Ghaderi A
    BMC Immunol; 2022 Nov; 23(1):56. PubMed ID: 36376825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both CD4+ and CD8+ T-cells in syngeneic islet grafts in NOD mice produce interferon-gamma during beta-cell destruction.
    Suarez-Pinzon W; Rajotte RV; Mosmann TR; Rabinovitch A
    Diabetes; 1996 Oct; 45(10):1350-7. PubMed ID: 8826970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells.
    Kooi S; Freedman RS; Rodriguez-Villanueva J; Platsoucas CD
    Lymphokine Cytokine Res; 1993 Dec; 12(6):429-37. PubMed ID: 8123759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer.
    Kumar P; Ranmale S; Mehta S; Tongaonkar H; Patel V; Singh AK; Mania-Pramanik J
    J Ovarian Res; 2023 Jun; 16(1):114. PubMed ID: 37322531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
    Lee M; Kim SW; Nam EJ; Cho H; Kim JH; Kim YT; Kim S
    Yonsei Med J; 2014 Nov; 55(6):1664-71. PubMed ID: 25323906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.